RxDoctor Payments Data

John Herzog, MD

Cardiovascular Disease · Greenville, MSNPI 1093734949

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,395 of the $5,687 with a category attached, or 77.3%. 26 manufacturers reported payments, led by Medtronic at 24.7% of the total.

$5,687in general payments, 2019–2025

Across 139 payments — averaging $40.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Penumbra, Inc.$1K
  • Cardiovascular Systems Inc.$683
  • Abbott$351
  • Terumo Medical Corporation$311
  • AstraZeneca$266
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$1,21721%
  • Food & beverage$4,39577%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,687 in reported general payments places this provider in the 60th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$866,313
Medicare patients
1,041
Services billed
12,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$288,313
FarxigaDapagliflozin Propanediol235$242,957
EntrestoSacubitril/Valsartan179$197,491
BrilintaTicagrelor255$178,927
XareltoRivaroxaban61$67,274
VerquvoVericiguat21$16,782
JardianceEmpagliflozin24$14,945
JanuviaSitagliptin Phosphate39$13,739
Metoprolol Succinate442$7,651
Nifedipine ErNifedipine218$6,306
Irbesartan226$4,676
Potassium Chloride185$3,977
Metolazone64$3,289
Cilostazol122$3,164
Sildenafil Citrate13$3,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$266$421,884490 claims
NovartisEntresto$60$197,491179 claims
Johnson & JohnsonXarelto$59$67,27461 claims
MerckVerquvo, Januvia$185$30,52260 claims
Boehringer IngelheimJardiance$46$14,94524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Greenville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →